US scientists have shown that texaphyrins can strongly bind lead and bismuth showing promise for future radiotherapeutic treatments of cancerous tumours.
ChemComm Associate Editor, Jonathan L. Sessler and colleagues from the University of Texas at Austin, have investigated the cytotoxicity of the stable texaphyrin complexes with ovarian cancer cells. Previous studies show that texaphyrin ligands accumulate in rapidly growing tissues, including cancerous lesions. So, to have now incorporated lead or bismuth – isotopes of which are commonly used in radiotherapy – into the texaphyrin structure makes a deadly combination for targeting and attacking cancerous cells.
Want to read more? Why not download the article today which is free to access until the 19th November.
Have you recently overcome a complex challenge? Why not submit your next set of exciting research results to ChemComm today.
